NYSE:ABBV - AbbVie Stock Price, News, & Analysis

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

AbbVie announced a quarterly dividend on Thursday, February 21st. Investors of record on Monday, April 15th will be given a dividend of $1.07 per share on Wednesday, May 15th. This represents a $4.28 dividend on an annualized basis and a yield of 5.39%. The ex-dividend date is Friday, April 12th. View AbbVie's Dividend History.

AbbVie announced that its board has initiated a stock repurchase program on Thursday, December 13th 2018, which authorizes the company to repurchase $5,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to buy up to 3.8% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company's leadership believes its stock is undervalued.

AbbVie Inc (NYSE:ABBV) issued its quarterly earnings results on Thursday, April, 25th. The company reported $2.14 earnings per share for the quarter, beating analysts' consensus estimates of $2.06 by $0.08. The company earned $7.83 billion during the quarter, compared to analysts' expectations of $7.81 billion. AbbVie had a net margin of 17.36% and a negative return on equity of 439.07%. The company's revenue was down 1.3% compared to the same quarter last year. During the same quarter last year, the business posted $1.87 earnings per share. View AbbVie's Earnings History.

AbbVie issued an update on its FY19 earnings guidance on Thursday, April, 25th. The company provided earnings per share (EPS) guidance of $8.73-8.83 for the period, compared to the Thomson Reuters consensus EPS estimate of $8.67. AbbVie also updated its FY 2019 guidance to $8.73-8.83 EPS.

17 brokers have issued twelve-month price targets for AbbVie's shares. Their forecasts range from $65.61 to $135.00. On average, they anticipate AbbVie's stock price to reach $94.0871 in the next twelve months. This suggests a possible upside of 18.6% from the stock's current price. View Analyst Price Targets for AbbVie.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 4 sell ratings, 8 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AbbVie.

News headlines about ABBV stock have been trending somewhat negative recently, InfoTrie reports. The research firm identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. AbbVie earned a media sentiment score of -1.1 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days.

AbbVie saw a increase in short interest during the month of April. As of April 15th, there was short interest totalling 27,575,807 shares, an increase of 20.4% from the March 29th total of 22,898,566 shares. Based on an average daily trading volume, of 4,952,645 shares, the days-to-cover ratio is presently 5.6 days. Approximately 1.9% of the company's shares are short sold. View AbbVie's Current Options Chain.

Some companies that are related to AbbVie include Johnson & Johnson (JNJ), Pfizer (PFE), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Novartis (NVS), Abbott Laboratories (ABT), Eli Lilly And Co (LLY), Novo Nordisk A/S (NVO), Sanofi (SNY), GlaxoSmithKline (GSK), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Celgene (CELG), Bayer (BAYRY) and Shire (SHPG).

Based on aggregate information from My MarketBeat watchlists, some companies that other AbbVie investors own include Intact Financial (IFC), Constellation Software (CSU), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), Vermilion Energy (VET), Wheaton Precious Metals (WPM), Rogers Communications (RCI), Open Text (OTEX), Valeant Pharmaceuticals Intl (VRX) and Toronto-Dominion Bank (TD).

AbbVie's stock is owned by many different of institutional and retail investors. Top institutional investors include Ellis Investment Partners LLC (0.19%), Ronna Sue Cohen (0.13%), Retirement Systems of Alabama (0.08%), Los Angeles Capital Management & Equity Research Inc. (0.05%), Gateway Investment Advisers LLC (0.05%) and Strs Ohio (0.05%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Brian L Durkin, Carlos Alban, Edward J Rapp, Glenn F Tilton, Henry O Gosebruch, Laura J Schumacher, Michael Severino, Richard A Gonzalez, Robert A Michael, Timothy J Richmond and William J Chase. View Institutional Ownership Trends for AbbVie.

ABBV stock was sold by a variety of institutional investors in the last quarter, including Ferguson Wellman Capital Management Inc., Calamos Advisors LLC, Los Angeles Capital Management & Equity Research Inc., Avalon Advisors LLC, Eastern Bank, Rhenman & Partners Asset Management AB, First American Bank and Pennsylvania Trust Co. Company insiders that have sold AbbVie company stock in the last year include Azita Saleki-Gerhardt, Brian L Durkin, Henry O Gosebruch, Laura J Schumacher, Michael Severino, Richard A Gonzalez, Timothy J Richmond and William J Chase. View Insider Buying and Selling for AbbVie.

ABBV stock was acquired by a variety of institutional investors in the last quarter, including Ellis Investment Partners LLC, Ronna Sue Cohen, Oakbrook Investments LLC, Factory Mutual Insurance Co., Pacer Advisors Inc., Decatur Capital Management Inc., 6 Meridian and Mercer Global Advisors Inc. ADV. Company insiders that have bought AbbVie stock in the last two years include Edward J Rapp and Glenn F Tilton. View Insider Buying and Selling for AbbVie.

Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ABBV stock can currently be purchased for approximately $79.34.

AbbVie has a market capitalization of $117.03 billion and generates $32.75 billion in revenue each year. The company earns $5.69 billion in net income (profit) each year or $7.91 on an earnings per share basis. AbbVie employs 30,000 workers across the globe.

The official website for AbbVie is http://www.abbvie.com.

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company can be reached via phone at 847-932-7900.